Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 423 recruiting now early-phase tilt #1 of 28,963 conditions

Breast Cancer: early-phase trial registry

423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1 of 28,963 conditions by registered trial count.

1,251 US clinical trials · 423 currently recruiting · #1 of 28,963 conditions by registered trial count

Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.

Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.

Open enrollment, early-phase tilt

Breast Cancer has 1,251 registered US clinical trials, 423 of them open to new participants right now, about 34% of the total.

423
recruiting participants now
34%
of trials open to enrollment
120
in Phase 3-4 (later-stage)
98
top sponsor: Memorial Sloan Kettering Cancer Center

Corpus placement: #1 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Breast Cancer is recruiting below its size-band peers.

    423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Breast Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.

  3. Typical Breast Cancer enrolment sits around 90 participants.

    Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.

  4. Breast Cancer research is mostly interventional.

    1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1235Phase 2256Phase 3100Phase 420

Open and recent trials

1,251 total, page 21 of 26

COMPLETED Phase 1 52 participants

Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer

Genentech

NCT01254526

COMPLETED NA 52 participants

Study of Barriers to Beginning and Finishing Treatment for Patients With Breast Cancer

City of Hope Medical Center

NCT00937989

COMPLETED 52 participants

Sentinel Lymph Node Mapping Post-Injection Site Pain

University of California, San Diego

NCT02065232

COMPLETED NA 51 participants

Using Technology to Improve Physical Activity Levels Among Postmenopausal Women (The Active & Aware Study)

University of California, San Diego

NCT01837147

COMPLETED NA 51 participants

Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer

Stanford University

NCT00533780

COMPLETED NA 51 participants

Psychosocial Outcomes in Online Cancer Support Groups

Christiana Care Health Services

NCT00382785

COMPLETED Phase 2 51 participants

Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer

Emory University

NCT00209092

COMPLETED Phase 2 50 participants

ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer

Mayo Clinic

NCT00110084

COMPLETED NA 50 participants

S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors

SWOG Cancer Research Network

NCT01453452

COMPLETED 50 participants

Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer

Beth Israel Deaconess Medical Center

NCT02666378

COMPLETED NA 50 participants

Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer

University of Michigan Rogel Cancer Center

NCT06228768

COMPLETED Phase 2 50 participants

Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy

Dana-Farber Cancer Institute

NCT00165204

COMPLETED 50 participants

Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)

Diagnostic Photonics

NCT01699867

COMPLETED NA 50 participants

Intellectual Impairment in Women With Breast Cancer

Stanford University

NCT00896324

COMPLETED 50 participants

Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients

University of Michigan Rogel Cancer Center

NCT01814397

COMPLETED Phase 3 50 participants

Therapy to Prevent Sexual Pain in Breast Cancer Survivors

OHSU Knight Cancer Institute

NCT01539317

COMPLETED NA 49 participants

Physical Activity, Fatigue, Sleep, and Inflammation

University of Alabama at Birmingham

NCT01147367

COMPLETED Phase 1 49 participants

An Exercise Intervention for Breast Cancer Patients: Feasibility and Effectiveness (BEAT Cancer Trial; Pilot Study)

University of Alabama at Birmingham

NCT00721565

COMPLETED NA 48 participants

Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

Roxane Laboratories

NCT01331421

COMPLETED Phase 2 48 participants

Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer

University of Miami

NCT00232479

COMPLETED Phase 1 48 participants

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences

NCT03629756

COMPLETED Phase 2 48 participants

Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer

National Cancer Institute (NCI)

NCT00179309

COMPLETED Phase 4 48 participants

A Comparison of Dermal Autograft to AlloDerm in Breast Reconstruction

University of Kentucky

NCT01561287

COMPLETED Phase 1 48 participants

A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)

Celldex Therapeutics

NCT00709462

COMPLETED NA 47 participants

Stay on Track: A Study of Exercise Effects During Radiation

Medical College of Wisconsin

NCT03243786

COMPLETED NA 47 participants

Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions

Roxane Laboratories

NCT01331434

COMPLETED Phase 2 46 participants

Multi-Omics Study of the Effect and Mechanisms of Acupuncture on Psychoneurological Symptoms Among Breast Cancer Survivors

University of Illinois at Chicago

NCT05417451

COMPLETED Phase 1 46 participants

A "Window Trial" on Boswellia for Breast Cancer Primary Tumors

Medical University of South Carolina

NCT03149081

COMPLETED NA 46 participants

Computerized Cognitive Training in Breast Cancer Survivors

Ohio State University

NCT05570604

COMPLETED Phase 2 46 participants

Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

NCT00006104

COMPLETED NA 45 participants

Initial Assessment of an Internet-based Symptom Management Intervention in Early Stage Breast Cancer

University of Michigan

NCT02495155

COMPLETED Phase 1 45 participants

Vaccine Therapy in Treating Patients With Breast Cancer

Memorial Sloan Kettering Cancer Center

NCT00004156

COMPLETED NA 44 participants

Healing Touch in Treating Fatigue in Women Undergoing Radiation Therapy for Breast Cancer

Vanderbilt-Ingram Cancer Center

NCT00574145

COMPLETED NA 44 participants

Educational Intervention for Reducing Work Disability in Breast Cancer Survivors

University of Wisconsin, Madison

NCT01799031

COMPLETED NA 43 participants

Promoting Resilience in Women With Breast Cancer

University of Alabama at Birmingham

NCT06133348

COMPLETED Phase 1 43 participants

A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Genentech

NCT02316509

COMPLETED Phase 2 43 participants

A Study of LY573636-sodium in Patients With Metastatic Breast Cancer

Eli Lilly and Company

NCT00992225

COMPLETED Phase 2 43 participants

Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery

University of California, San Francisco

NCT00305825

COMPLETED Phase 1 42 participants

Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen

Sanofi

NCT01042925

COMPLETED Phase 1 41 participants

Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2

University of California, San Francisco

NCT00544804

COMPLETED Phase 2 41 participants

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

City of Hope Medical Center

NCT00003042

COMPLETED Phase 1 41 participants

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Relay Therapeutics

NCT05759949

COMPLETED NA 41 participants

Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment

Washington University School of Medicine

NCT02891681

COMPLETED NA 40 participants

Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer

Jaroslaw Hepel

NCT01463007

COMPLETED Phase 2 40 participants

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

St. Vincent Medical Center - Los Angeles

NCT00002475

COMPLETED 40 participants

An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg

University of Kansas

NCT00291109

COMPLETED Phase 2 40 participants

Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer

Georgetown University

NCT00003035

COMPLETED NA 40 participants

e-CHEC-uP: Scaling up an Efficacious Cancer Screening Intervention for Women With Limited English

Johns Hopkins University

NCT03726619

COMPLETED Phase 4 40 participants

Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer

Kettering Health Network

NCT02287675

COMPLETED NA 40 participants

The Women's Healthy Lifestyle Study

University of Michigan

NCT00583726

← Previous Page 21 of 26 Next →

Phase Distribution

PhaseTrial count
Phase 1 235
Phase 2 256
Phase 3 100
Phase 4 20

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What is open for Breast Cancer right now

423 recruiting of 1,251 indexed (34% open).

Phase mix: 120 late (III/IV) vs 491 early (I/II) (early-phase heavy).

Top sponsor: Memorial Sloan Kettering Cancer Center (98 trials), 9 others listed. 50 shown below, recruiting first. #1 of 28,963 conditions by registered trial count.

How open-enrollment share is computed

Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.

Frequently Asked Questions

How many clinical trials are there for Breast Cancer?

PlainTrial tracks 1,251 US clinical trials for Breast Cancer, of which 423 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Breast Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.